New hope for Tough-to-Treat esophageal cancer
NCT ID NCT07188103
Summary
This study is testing a new combination treatment for people with advanced esophageal cancer that has worsened after their first treatment. It combines an immunotherapy drug called Ivonescimab with a short, intense course of radiation. The main goals are to see if this approach can slow the cancer's growth and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincal Hospital
RECRUITINGHefei, Anhui, 230000, China
Conditions
Explore the condition pages connected to this study.